CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Inclusion Criteria

• •Newly diagnosed:
• •* Therapy-related acute myeloid leukemia (AML)
• •* AML with antecedent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
• •* AML with MDS-related changes (as per World Health Organization \[WHO\])
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
• •Plasma creatinine =\< 1.5 x upper limit of normal (ULN)
• •Total bilirubin \< 2.0 mg/dL
• •Serum alanine aminotransferase and aspartate aminotransferase \< 3 x ULN
• •Left ventricular ejection fraction by echocardiogram or multiple-gated acquisition \>= 50%
• •Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• •Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment and commit to two forms of birth control
• •Men must use a latex condom during any sexual contact with women of childbearing potential
• •Willing to adhere to protocol specific requirements
• •Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure